Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Scientists at Johns Hopkins have finally solved an 18-year-old mystery: how a common gut bacterium triggers colorectal cancer. Using CRISPR, they identified claudin-4 as the docking protein for the bacterial toxin BFT — and even developed a molecular decoy that successfully blocked the toxin in mice, hinting at a new prevention strategy.
For nearly two decades, scientists knew that Bacteroides fragilis — a bacterium found in the guts of up to 20% of healthy people — could produce a toxin linked to colorectal cancer, but couldn't figure out how it got started. Now, a Johns Hopkins-led team has cracked it. Using CRISPR gene-editing, they identified claudin-4, a protein that helps seal the gut lining, as the critical docking point for the bacterial toxin BFT. Without this attachment, the toxin can't launch its attack on the colon's protective barrier.
The discovery didn't stop at explanation — it sparked a solution. Researchers engineered a molecular decoy mimicking claudin-4 that lures BFT away from colon cells. In mouse experiments, the decoy successfully intercepted the toxin and prevented tissue damage, opening the door to potential new therapies. The findings were published in Nature.
Key Takeaways:
Why it matters: Colorectal cancer is one of the leading causes of cancer death worldwide. Identifying a targetable entry point for a cancer-promoting bacterial toxin could pave the way for new prevention and treatment strategies — potentially before the damage even begins.
